Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S100A4-TfR bispecific antibody
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The S100A4-TfR bispecific antibody (BsA) is a preclinical-stage biologic engineered to treat glioblastoma (GBM) by overcoming the blood-brain barrier (BBB). It features a dual-targeting mechanism: one arm binds to S100A4 (Protein S100-A4), a protein that regulates stemness, epithelial-mesenchymal transition (EMT), and immunosuppressive phenotypes in the tumor microenvironment; the second arm targets the Transferrin Receptor (TfR1) to facilitate robust BBB penetration through receptor-mediated transcytosis. By blocking S100A4, the antibody aims to reprogram myeloid and T cells toward a pro-inflammatory state, increase CD4+ T cell infiltration, and reduce the self-renewal capacity of glioma stem cells. It is currently being developed by the University of Texas Health Science Center at Houston and the Houston Methodist Research Institute.
- Other names
- bispecific S100A4/TfR antibodyS100A4/TfR BsA
02
Targets
S100A4 (Ferroptosis suppressor protein 1)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on S100A4-TfR bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S100A4-TfR bispecific antibody.